GI Partners executes market move in market

Novartis Acquisition Spree Continues with Avidity Biosciences Buyout

Deal Background and Motivations

Novartis, the Swiss pharmaceutical giant, has been on an acquisition spree over the past year, acquiring more than 35 companies as it seeks to offset the impact of generic competition on its blockbuster drugs. The company’s latest move is the announced acquisition of U.S. biotechnology firm Avidity Biosciences for around $12 billion, its biggest deal in a decade.

The acquisition will give Novartis access to Avidity’s promising pipeline of experimental drugs, with two of the company’s three leading drug candidates expected to be launched before 2030 and potentially generating billions in sales. Novartis CEO Vas Narasimhan emphasized the strategic fit, stating that the deal was “driven by science and the technology” and that Novartis has the “adequate firepower” to execute such transactions due to its strong free cash flow of nearly $20 billion per year.

Sector and Market Signals

• The acquisition reflects the ongoing consolidation in the pharmaceutical industry as companies seek to bolster their pipelines and offset the impact of generic competition.
• Novartis’s performance in the third quarter was mixed, with a 7% increase in constant currency sales offset by the negative impact of loss of exclusivity for some of its key drugs, resulting in a 25% jump in net income that still fell short of analyst expectations.
• The company’s shares fell 3.4% at the start of trading following the earnings release, despite Novartis’s track record of raising guidance for the past 10 quarters, including twice this year.

Implications for Private Equity

The Novartis acquisition of Avidity Biosciences highlights the continued appetite for M&A activity in the pharmaceutical sector, particularly in the area of biotechnology and innovative drug development. Private equity firms with expertise in the healthcare and life sciences sectors may find opportunities to partner with or acquire promising biotech companies that could be attractive targets for larger pharmaceutical players like Novartis.

Immediate Outlook

Investors will be closely watching for any further developments in Novartis’s acquisition strategy, as well as the company’s ability to navigate the challenges posed by generic competition and pricing pressures. Additionally, the market will be monitoring the potential impact of any “most favored nation” (MFN) agreements between pharmaceutical companies and the U.S. government, which could affect drug pricing and earnings for the industry.

Key Takeaways

• Novartis continues its acquisition spree, acquiring Avidity Biosciences for around $12 billion to bolster its pipeline of promising experimental drugs.
• The deal reflects the ongoing consolidation in the pharmaceutical industry as companies seek to offset the impact of generic competition and strengthen their product portfolios.
• Private equity firms with expertise in the healthcare and life sciences sectors may find opportunities to partner with or acquire promising biotech companies that could be attractive targets for larger pharmaceutical players.

Sources

• CNBC Europe